Spanish government to publish strong data on GW's Sativex

Porton Down, UK-based GW Pharmaceuticals says that the government of Catalonia in Spain has published positive results from its pilot program to evaluate its cannabinoid nasal spray Sativex as a treatment for high-need patients suffering from a range of medical conditions. Stephen Wright, GW's R&D director, said this program has shown that Sativex provides "important improvements in approximately half of high-need patients who have otherwise failed to gain benefit from currently-available medicines."